Search

Displaying results 861 - 870 of 2816 in total
  1. Drug

    Fecal microbiota

    go.drugbank.com/drugs/DB17743
    ApprovedInvestigational

    [A259177] The purpose of fecal microbiota transplantation is to restore gut microbiota and replace microbes with healthy host microbiota.

  2. Drug

    TG100-115

    go.drugbank.com/drugs/DB05552
    Investigational

    An NSAID that inhibits PI-3K gamma and delta.

  3. Drug

    PF-05230907

    go.drugbank.com/drugs/DB18417
    Investigational

    PF-05230907 is a recombinant activated Factor X variant.

  4. Drug

    Firocoxib

    go.drugbank.com/drugs/DB09217
    ExperimentalVet approved

    It currently approved for veterinary use in dogs and horses under the brand names Equioxx and Previcox. Firocoxib was the first COX-2 inhibitor approved by the U.S.

  5. Drug

    Fimasartan

    go.drugbank.com/drugs/DB09279
    Investigational

    Fimasartan was initially approved September 9th, 2010 in South Korea and is marketed under the brand name _Kanarb_ by Boryung Pharmaceuticals.

  6. Drug

    Calcitonin porcine

    go.drugbank.com/drugs/DB13189
    Experimental

    The first commercially available preparation in Britain was porcine calcitonin (brand name Calcitare).

  7. Drug

    Diamorphine

    go.drugbank.com/drugs/DB01452
    ApprovedIllicit

    Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United...

  8. Drug

    PH-797804

    go.drugbank.com/drugs/DB07941
    Investigational

    PH-797804 has been investigated for the treatment of Osteoarthritis.

  9. Drug

    Atazanavir

    go.drugbank.com/drugs/DB01072
    ApprovedInvestigational

    Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class.

    Categories: P-glycoprotein inducers, P-glycoprotein inhibitors
  10. Drug

    Danvatirsen

    go.drugbank.com/drugs/DB14825
    Investigational

    Danvatirsen is under investigation in clinical trial NCT03334617 (Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy.).